(HealthDay)—For patients with clear-cell renal cell carcinoma at high risk for recurrence after nephrectomy, adjuvant therapy with pembrolizumab improves disease-free survival, according to a study published in the Aug. ...
Aug 19, 2021
0
13
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy ...
Jun 4, 2021
0
3
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings ...
Jun 3, 2021
0
1
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from ...
Feb 13, 2021
0
5
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 ...
Jan 30, 2021
0
3
(HealthDay)—For the first-line treatment of microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer, pembrolizumab is superior to chemotherapy for prolonging progression-free ...
Dec 3, 2020
0
0
Some people with head and neck cancer will now have access to the immunotherapy drug pembrolizumab (Keytruda) on the NHS in England.
Oct 27, 2020
0
3
A drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be beneficial in a small study involving ten patients. The results, which appeared July 1, 2020, in Science ...
Jul 2, 2020
0
365
A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of ...
May 29, 2020
0
3
Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically ...
May 6, 2020
0
0
